Full Press Release Details
Immutep to Announce New TACTI-002 Data at the
2022 World Conference on Lung Cancer
SYDNEY, AUSTRALIA 27 June 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or
the Company ), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new data from
second line non-small cell lung cancer patients (Part B) in the Phase II TACTI-002 trial has been selected for a poster presentation at the IASLC 2022 World Conference
on Lung Cancer (WCLC 2022) taking place in-person and online from 6-9 August 2022 in Vienna, Austria.
The abstract for the poster will be available from 6:00 pm EST on 8 July 2022 at wclc2022.iaslc.org and will subsequently be made available on
Immutep s website at www.immutep.com.
The poster presentation including an audio recording by
TACTI-002 Principal Investigator, Prof Martin Forster, will also be made available after the poster presentation session (date below).
| Title: | TACTI-002: A phase II study of eftilagimod alpha (soluble LAG-3) & pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic NSCLC | |
| Session Title: | Metastatic Non-small Cell Lung Cancer Immunotherapy | |
| Session Number: | EP08.01 | |
| Presentation Session: | 7-8 August 2022, 9:45 am 6:00 pm CET | |
| Presenting Author: | Martin Forster M.D., Ph.D., University College London | |
| Control #: | 82 |
the world s largest international gathering of clinicians, researchers and scientists in the field of lung cancer and thoracic oncology. It is held by the International Association for the Study of Lung Cancer (IASLC) which is a global network
of more than 8,000 lung and thoracic cancer specialists from all disciplines dedicated to the study and eradication of lung cancer and other thoracic malignancies. Visit wclc2022.iaslc.org for more.
TACTI-002 (Two ACTive Immunotherapies) is a Phase II clinical trial being conducted in collaboration with Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada).
The study is evaluating the combination of Immutep s eftilagimod alpha with MSD s KEYTRUDA (pembrolizumab) in up to 189 patients with second line head and neck squamous cell
carcinoma (HNSCC) or non-small cell lung cancer (NSCLC) in first and second line.
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related
immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.
Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
Immutep s current lead product
candidate is eftilagimod alpha ( efti or IMP321 ), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for
autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep s large pharmaceutical partners.
Further information can be found on the Company s website www.immutep.com or by contacting:
Australian Investors/Media:
+61 (0)406 759 268; cstrong@citadelmagnus.com
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com
announcement was authorised for release by the CEO of Immutep Limited, Marc Voigt.
Immutep Limited, Level 33, Australia Square
264 George Street, Sydney NSW 2000